This is not a case of same-same, the Canon result is excellent.
Achieving a bladder cancer treatment was noted as 15% chance of success in Edison's NPV calcs. I'm expecting a re-rate based on the Canon trial update alone; it is excellent news.
The pancreatic cancer news is just test tube stuff at the moment so I would get too excited.
More updates to follow tomorrow (with the market's full attention): CAPRA, STORM & MITCI trials.
VLA Price at posting:
92.0¢ Sentiment: Buy Disclosure: Held
